Awaiting development: Guidance and quality standards

Showing 221 to 230 of 284

Guidance and quality standards awaiting development
Title	Type
Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]	Technology appraisal guidance
Semaglutide for treating type 2 diabetes [ID1450]	Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older [ID6542]	Technology appraisal guidance
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]	Technology appraisal guidance
Sibeprenlimab for treating IgA nephropathy [ID6604]	Technology appraisal guidance
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]	Technology appraisal guidance
Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]	Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]	Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]	Technology appraisal guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]	Technology appraisal guidance